PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.

Abstract Lung cancer is the most common cause of cancer death. About 80% of patients are diagnosed at stage III in the non-small cell lung cancer (NSCLC). It is extremely important to understand the progression of this disease which has low survival times despite the advancing treatment modalities. We aimed to investigate the relationship between early tumor shrinkage (ETS) after initial concurrent chemoradiotherapy (C-CRT) and survival outcome in patients with stage III (NSCLC).
PMID
Related Publications

Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.

Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.

Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.

Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.

Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.

Authors

Mayor MeshTerms

Carcinoma, Non-Small-Cell Lung

Lung

Lung Neoplasms

Tumor Burden

Keywords
Journal Title medicine
Publication Year Start




PMID- 29742701
OWN - NLM
STAT- MEDLINE
DCOM- 20180515
LR  - 20180515
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 19
DP  - 2018 May
TI  - Early tumor shrinkage served as a prognostic factor for patients with stage III
      non-small cell lung cancer treated with concurrent chemoradiotherapy.
PG  - e0632
LID - 10.1097/MD.0000000000010632 [doi]
AB  - BACKGROUND: Lung cancer is the most common cause of cancer death. About 80% of
      patients are diagnosed at stage III in the non-small cell lung cancer (NSCLC). It
      is extremely important to understand the progression of this disease which has
      low survival times despite the advancing treatment modalities. We aimed to
      investigate the relationship between early tumor shrinkage (ETS) after initial
      concurrent chemoradiotherapy (C-CRT) and survival outcome in patients with stage 
      III (NSCLC). METHODS: A retrospective review of 103 patients with stage III NSCLC
      who had received C-CRT from January 2006 to October 2011 was performed. Patients 
      were treated with systemic chemotherapy regimen of Cisplatin/Vp-16 and concurrent
      thoracic radiotherapy at a median dose of 66 Gy (range 60-70 Gy). All patients
      received a computed tomography (CT) examination before treatment. Also
      subsequently, chest CT scans were performed with the same imaging parameters at
      approximately 5 weeks after the initiation of treatment. ETS is here stratified
      by a decrease in tumor size >/=30% and <30% in the longest dimension of the
      target lesion within 5 weeks. RESULTS: Of the 103 patients, 59 ones showed a 30% 
      decrease in tumor size, and the rest displayed a decrease of <30%. ETS showed no 
      significant correlation with age, T classification, N classification,
      histological classification, smoking status, G classification, EGFR status, or
      acute pulmonary toxicity. In the current retrospective clinical study,
      Kaplan-Meier curves showed that patients with ETS >/= 30% had a better
      progression-free survival and overall survival. The univariate and multivariate
      Cox regression analyses indicated that ETS < 30% was associated with a
      significantly increased risk of cancer-related death (P < .05) in stage IIINSCLC.
      CONCLUSIONS: ETS may be served as a useful prognostic factor to predict the
      outcome of stage III NSCLC patients treated with CCRT.
FAU - Wei, Min
AU  - Wei M
AD  - Department of Oncology.
FAU - Ye, Qingqing
AU  - Ye Q
AD  - Department of Surgical Oncology, First Affiliated Hospital of Yangtze University,
      Jingzhou, Hubei, China.
FAU - Wang, Xuan
AU  - Wang X
AD  - Department of Oncology.
FAU - Wang, Men
AU  - Wang M
AD  - Department of Oncology.
FAU - Hu, Yan
AU  - Hu Y
AD  - Department of Oncology.
FAU - Yang, Yonghua
AU  - Yang Y
AD  - Department of Oncology.
FAU - Yang, Jiyuan
AU  - Yang J
AD  - Department of Oncology.
FAU - Cai, Jun
AU  - Cai J
AD  - Department of Oncology.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - Q20Q21Q62J (Cisplatin)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents/administration & dosage
MH  - *Carcinoma, Non-Small-Cell Lung/diagnosis/pathology/physiopathology/therapy
MH  - Chemoradiotherapy/*methods
MH  - China
MH  - Cisplatin/*administration & dosage
MH  - Female
MH  - Humans
MH  - *Lung/diagnostic imaging/pathology
MH  - *Lung Neoplasms/diagnosis/pathology/physiopathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Tomography, X-Ray Computed/methods
MH  - Treatment Outcome
MH  - *Tumor Burden/drug effects/radiation effects
EDAT- 2018/05/10 06:00
MHDA- 2018/05/16 06:00
CRDT- 2018/05/10 06:00
PHST- 2018/05/10 06:00 [entrez]
PHST- 2018/05/10 06:00 [pubmed]
PHST- 2018/05/16 06:00 [medline]
AID - 10.1097/MD.0000000000010632 [doi]
AID - 00005792-201805110-00020 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 May;97(19):e0632. doi: 10.1097/MD.0000000000010632.